Brief: EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo
14/11/2025 11:47
Nov 14 (Reuters) - EMA's CHMP: EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR KOSELUGO EMA'S CHMP: RECOMMENDS MARKETING AUTHORISATION FOR DAWNZERA - WEBSITE EMA'S CHMP: INLURIYO RECEIVES POSITIVE OPINION EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WASKYRA (ETUVETIDIGENE AUTOTEMCEL), FIRST GENE THERAPY TO TREAT WISKOTT-ALDRICH SYNDROME EMA'S CHMP: ADOPTS POSITIVE OPINION FOR TEIZEILD EMA'S CHMP: APPLICATION FOR OHTUVAYRE WITHDRAWN EMA'S CHMP: APPLICATION FOR NURZIGMA WITHDRAWN EMA'S CHMP: TEDUGLUTIDE RECEIVES POSITIVE OPINION Source text: [ID:] Further company coverage: AZN.L ((Reuters.Briefs@thomsonreuters.com))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug